Gianna Musettini

Livorno, 57124, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

A Perspective on a Possible New Role for Bevacizumab Combined with Paclitaxel in Hormone-Resistant Metastatic Breast-Cancer Patients.

A Perspective on a Possible New Role for Bevacizumab Combined with Paclitaxel in Hormone-Resistant Metastatic Breast-Cancer Patients.

Journal: Journal of clinical medicine

Published: June 16, 2026

Current Landscape and Evolving Role of Targeted Agents in Urothelial Carcinoma.

Current Landscape and Evolving Role of Targeted Agents in Urothelial Carcinoma.

Journal: Cancers

Published: December 21, 2025

Mixed endometrial carcinoma: is it time to profile the two components separately?

Mixed endometrial carcinoma: is it time to profile the two components separately?

Journal: Frontiers in oncology

Published: October 30, 2025

Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival.

Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival.

Journal: Oncology research

Published: September 25, 2025

Immunotherapy-induced eczema treated with dupilumab.

Immunotherapy-induced eczema treated with dupilumab.

Journal: Journal of the European Academy of Dermatology and Venereology : JEADV

Published: August 29, 2023

Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study.

Non-pegylated liposomal doxorubicin in older adjuvant early breast cancer patients: cardiac safety analysis and final results of the COLTONE study.

Journal: Clinical and experimental medicine

Published: May 18, 2023

Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer.

Early increase of plasma soluble VEGFR-2 is associated with clinical benefit from second-line treatment of paclitaxel and ramucirumab in advanced gastric cancer.

Journal: American journal of cancer research

Published: March 02, 2022

HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer.

HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer.

Journal: The oncologist

Published: December 02, 2019

Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy.

Systematic Review of adverse events reporting in clinical trials leading to approval of targeted therapy and immunotherapy.

Journal: Future oncology (London, England)

Published: June 27, 2019

Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan.

Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan.

Journal: Clinical colorectal cancer

Published: January 22, 2019

The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer.

The emerging role of liquid biopsy in diagnosis, prognosis and treatment monitoring of pancreatic cancer.

Journal: Pharmacogenomics

Published: December 07, 2018

Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.

Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: October 16, 2018

Showing 1-12 of 25

Last Updated: 09/26/2026